Business Partnership for Development and Commercialization of Medical Device Implant Utilizing MSC2 for the Regeneration of Esophageal Tissue in Humans
1. Overview of the business partnership
Under the partnership agreement, SanBio will grant D&P a non-exclusive, non-transferable license to use MSC2 for the development and commercialization of the latter’s regenerative esophageal implant. In return, the Company will receive rights to commercialize D&P’s regenerative esophageal implant in
In terms of major expenses, SanBio will cover expenses required for the development of manufacturing processes of MSC2 while D&P will shoulder expenses for the development of the regenerative esophageal implant in all countries except
D&P has extensive knowledge and highly specialized expertise in the field of regenerative esophageal implants. We believe our collaboration with D&P, which includes the supply of MSC2, will lead to development of a medical device implant that can provide substantial potential benefits to patients suffering from esophageal damages.
Dr.
We at D&P Bioinnovations are pleased to cooperate with SanBio, a leader in regenerative medicine research development, in our development of regenerative esophageal implants. D&P is a regenerative medicine company focused on repairing damaged tissue/organs with engineered biomaterials and stem cells. We look forward to collaborating with SanBio on the development of our off-the-shelf engineered platform organ regenerative implant for our first application to treat and regenerate a severely damaged esophagus due to cancer, illness, and/or physical trauma. This collaboration is exciting to continue our work in changing and translating the paradigm of regenerative medicine therapeutics through the use of D&P’s novel engineered off-the-shelf tissue/organ regenerative implants.
2. Overview of business partner
(1) |
Company name |
|
(2) |
Location |
|
(3) |
|
|
(4) |
Main business |
Development of platform tissue/organ regenerative implants: 1st application to develop regenerative esophageal implants. |
(5) |
Date established |
March, 2015 |
3. Outlook
The impact of the newly published analytical results on earnings for the current fiscal year (ending
View source version on businesswire.com: https://www.businesswire.com/news/home/20211115006394/en/
For more information, contact:
info@sanbio.jp
Source: